“Development of polyvalent vaccines for prevention of Group A Streptococcal infections”

QTHA 2013 Electronic Seminar Series
James Cook University School of Public Health, Tropical Medicine and Rehabilitation Sciences presents

What: "Development of polyvalent vaccines for prevention of Group A Streptococcal infections", Dr David McMillan, University of the Sunshine Coast
When & Where: Wednesday 29th May 2013, 4 pm JCU, Cairns Campus, A3.3 Videolinked to JCU Townsville Aust. Tropical Science & Innovation Precinct room 030 (145-030)

Diseases associated with Streptococcus pyogenes (Group A streptococcus, GAS) account for half a million human deaths each year. These deaths predominantly occur in developing countries, and Indigenous groups within developed nations. The Australian Indigenous population is particularly susceptible to streptococcal disease, with rates of disease far exceeding that of the Caucasian population. The morbidity and mortality associated with GAS infection have spurred research into the development of a safe efficacious GAS vaccine that prevents primary infection. The M-protein, the most abundant protein on the surface of GAS, is also a favoured vaccine candidate. The M-protein consists of a hyper-variable amino-terminus, followed by a number of repeat regions that demonstrate increasing conservation. As the central region of the M-protein includes epitopes that induce immunologically cross-reactive immune responses that contribute to RHD a full length M-protein is not a viable optional as a vaccine candidate. Most M-protein based strategies have focussed on shorter immunogenic regions of the M-protein. Our approach to GAS vaccine development has been to identify and link variant sequences of the M-protein as single fusion proteins. This seminar will describe our progress in the development of vaccines against GAS, a pathogen which is one of the top ten infectious killers of humans.

Download a flyer

web design by precedence